Expression And Clinical Significance Of CD133 And Musashi-2 In Ovarian Serous Carcinomas

Background:According to the latest global cancer statistics in 2018,the number of people suffering from ovarian cancers and the number of people dead from ovarian cancers account for 3.4% and 4.4% of cancer cases in woman.Both figures ranked 8th among malignant tumors in woman.Ovarian cancer is the third common gynecological malignancies following by breast cancer and cervical cancer.Cancer stem cells(CSCs)are undifferentiated tumor cells,which have the abilities of unlimited proliferation,self-renew,growth and differentiation.The eradication of CSCs might be a hopeful cure for ovarian cancer.High expression of CD133 speeds up the formation,progression,metastasis and recurrence of many types of cancer.CD133 is considered as markers of CSCs in a variety of cancers.Musashi-2(MSI-2)is a relatively conserved RNA-binding protein whose high expression is associated with leukemia,esophageal cancer,gastric cancer,liver cancer,colon cancer,breast cancer,lung cancer,pancreatic cancer,bladder cancer,cervical cancer,etc.High expression of MSI-2 also predict poor prognosis of diseases.Objective:By comparing the expression level of CD133 and Musashi-2(MSI-2)in ovarian serous carcinomas and ovarian serous cystadenomas,and analyzing the relationship between expression level of CD133 and MSI-2 in ovarian serous carcinomas and clinical indicators,we are hoping to provide evidence for the diagnosis and treatment of ovarian serous carcinomas.Methods:Collecting 69 ovarian samples in patients who had undergone surgeries in the Second Hospital of Jilin University from September 2012 to February 2014 and whose pathologies had already been confirmed(including 49 cases of ovarian serous carcinomas and 20 cases of ovarian serous cystadenomas).The ovarian tissues are made into paraffin sections,and the amount of CD133 and MSI-2 are identified respectively by immunohistochemical method.This research aim to explore the relationship between the two indicators in these two disease groups and to analyze the relationship between the expression of CD133 and MSI-2 and clinical indicators such as clinical stage,5-year survival,lymph node metastasis and tissue differentiation of ovarian serous carcinomas.Results:1.The positive rates of CD133 expression in ovarian serous cystadenoma and ovarian serous carcinomas are 20.00% and 51.02%,respectively,and the difference is statistically significant(P<0.05).There is a statistically significant difference in the positive rate of CD133 in the patients with lymph node metastasis(68.18%)and those without lymph node metastasis(37.04%)(P<0.05).The positive rates of CD133 in patients alive and dead 5 years after surgery for ovarian serous carcinoma are 31.82% and 66.87%,respectively,and the difference is statistically significant(P<0.05).The positive rate of CD133 in the advanced stage of ovarian serous carcinomas(III-IV)(57.14%)is higher than that in the early stage(I-II)(35.71%),but the difference was not statistically significant(P>0.05).There are no significant differences between the expression of CD133 and clinical indicators such as age,menstrual status,ascites,and tissue differentiation of ovarian serous carcinomas(P>0.05).2.The positive rates of MSI-2 in ovarian serous cystadenoma and ovarian serous carcinomas are 20.00% and 67.35%,respectively,and the difference is statistically significant(P<0.05).The positive rates of MSI-2 in early stage(I-II)and advanced stage(III-IV)in ovarian serous carcinomas are 42.86% and 77.14%,respectively,and there are statistical differences(P<0.05).The positive rates of CD133 in patients alive and dead 5 years after surgery for ovarian serous carcinomas are 50.00% and 81.48%,respectively,and the difference is statistically significant(P<0.05).There are no significant differences between the expression of MSI-2 and clinical indicators such as age,menstrual status,ascites,node metastasis,and tissue differentiation of ovarian serous carcinoma(P>0.05).3.There is a weak positive correlation between the expression of CD133 and MSI-2 in ovarian serous carcinomas after tested by the method of Spearman correlation test,and the correlation coefficient is ?=0.362,P<0.05.Conclusions:1.The positive expression rates of CD133 and MSI-2 in ovarian serous carcinomas are significantly higher than those in ovarian serous cystadenoma,and CD133 and MSI-2 are expected to be diagnostic indicators of ovarian serous carcinomas.2.CD133 and MSI-2 are significantly correlated with cancer progression indicators of ovarian serous carcinomas such as lymph node metastasis,clinical stage,respectively.The positive expression rates of both of them in patients who died 5 years after surgery is significantly higher than that in patients who survived 5 years after surgery.CD133 and MSI-2 are expected to become CSCs markers of ovarian serous carcinomas and predict the prognosis of patients with ovarian serous carcinomas.